Author: Rachel Beham, PharmD Educational Pearls: There are currently many Ebola vaccines that are being studied, and one (recombinant VZV-Ebola vaccine) is currently being used in Africa. This vaccine has so far shown good efficacy in reducing Ebola infections and mortality from Ebola in those who do become infected.  There are antibody-based treatments that are currently under investigation for the treatment of Ebola. They have been well tolerated in phase 1 trials and show some promise of efficacy.   References Shcheblyakov D et. al. Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection. Antiviral Res. 2019 Oct 5:104617. doi: 10.1016/j.antiviral.2019.104617. [Epub ahead of print] Fries L et. al. A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults. J Infect Dis. 2019 Oct 11. pii: jiz518. doi: 10.1093/infdis/jiz518. [Epub ahead of print]  Summarized by Will Dewispelaere, MS4 | Edited by Erik Verzemnieks, MD Music credit: “Smooth Lovin” by Kevin MacLoed (incompetech.com). Licensed under Creative Commons By Attribution 3.0 License. http://creativecommons.org/licenses/by/3.0/